In vitro fertilisation

Bridge Clinic opens new clinic for IVF services in Central London

Retrieved on: 
Tuesday, May 16, 2023
Transfer, Heart, Communication, Uterus, Bombings of King's Cross and Euston stations, Doctor of Philosophy, Freezing, IVF, IUI, Trust, Walking, Erramatti Mangamma, Patient, Human Fertility (British Fertility Society journal), Fertility, King's Cross, ICSI, Ovulation induction, Health, FET, Family, BPAS, OI, In vitro fertilisation, Intracytoplasmic morphologically selected sperm injection, Hospital, Birth control, Nursing, Dentistry, Euston, Embryology

LONDON, May 16, 2023 /PRNewswire/ -- A new affordable, accessible Fertility clinic in central London aims to improve and innovate the patient experience. Bridge Clinic London offers a fully comprehensive range of the leading fertility services, with an approach centred on compassionate care for all patients at an affordable price. Its whole-clinic multidisciplinary approach to patient care ensures seamless communication, comprehensive medical review and, crucially, ensures patients feel heard and understood.

Key Points: 
  • Bridge Clinic London offers a fully comprehensive range of the leading fertility services, with an approach centred on compassionate care for all patients at an affordable price.
  • Marta Jansa Perez, Director of Embryology, at Bridge Clinic London said: "At Bridge Clinic London we understand that fertility treatment can be a stressful and emotional experience.
  • The Bridge Clinic London team has a vast amount of experience in this sector and we pride ourselves on this."
  • Conveniently located in the heart of central London, between King's Cross and Euston stations, the clinic is intentionally accessible.

Bridge Clinic opens new clinic for IVF services in Central London

Retrieved on: 
Tuesday, May 16, 2023
Transfer, Heart, Communication, Uterus, Multimedia, Bombings of King's Cross and Euston stations, Doctor of Philosophy, Freezing, IVF, IUI, Trust, Walking, Erramatti Mangamma, Patient, Human Fertility (British Fertility Society journal), Fertility, King's Cross, ICSI, Ovulation induction, Health, FET, Family, BPAS, OI, In vitro fertilisation, Intracytoplasmic morphologically selected sperm injection, Hospital, Birth control, Nursing, Dentistry, Euston, Embryology

LONDON, May 16, 2023 /PRNewswire/ -- A new affordable, accessible Fertility clinic in central London aims to improve and innovate the patient experience. Bridge Clinic London offers a fully comprehensive range of the leading fertility services, with an approach centred on compassionate care for all patients at an affordable price. Its whole-clinic multidisciplinary approach to patient care ensures seamless communication, comprehensive medical review and, crucially, ensures patients feel heard and understood.

Key Points: 
  • Bridge Clinic London offers a fully comprehensive range of the leading fertility services, with an approach centred on compassionate care for all patients at an affordable price.
  • Marta Jansa Perez, Director of Embryology, at Bridge Clinic London said: "At Bridge Clinic London we understand that fertility treatment can be a stressful and emotional experience.
  • James Barr, Managing Director, at Bridge Clinic London said: "Not only have we invested in our technology but also our team.
  • The Bridge Clinic London team has a vast amount of experience in this sector and we pride ourselves on this."

Global Fetal Bovine Serum Market Report 2022: Rising Demand for Fetal Bovine Serum for Research Studies Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, Pharmaceutical, Health, Observation, Academic institution, Porter's five forces analysis, COVID-19, Risk, Fertilisation, Geography, Growth, Ansoff Matrix, Market development, USD, In vitro fertilisation, Drug discovery, Medium (website), CAGR, SWOT, Stem cell, Vaccine, Pharmaceutical industry, Risk management, Chromatography, Industry, Application, Diagnosis

The Global Fetal Bovine Serum Market is segmented based on Product, Application, End-user, and Geography.

Key Points: 
  • The Global Fetal Bovine Serum Market is segmented based on Product, Application, End-user, and Geography.
  • By Product, the market is classified into Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted, Stem Cell.
  • The report presents a detailed Ansoff matrix analysis for the Global Fetal Bovine Serum Market.
  • The report offers a comprehensive evaluation of the Global Fetal Bovine Serum Market.

Assisted Reproductive Technology Global Market Report 2022: Diagnosis, Procedure Type, End-User, and Covering Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 8, 2022
Health, Women, Consumer, Other Health, Woman, Growth, Cook Group, Thermo Fisher Scientific, FER, UCLA Health, Infertility, Fertility clinic, Hospital, Diagnosis, Merck Group, Assisted reproductive technology, ART, Organization, Biotechnology, IVF, Failure, Man, Egg, Genetics, Pregnancy, Child, In vitro fertilisation, Medical device, Birth control

The "Assisted Reproductive Technology Global Market Report 2022: By Diagnosis, Procedure Type, End-User, and Covering" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Assisted Reproductive Technology Global Market Report 2022: By Diagnosis, Procedure Type, End-User, and Covering" report has been added to ResearchAndMarkets.com's offering.
  • The assisted reproductive technology (ART) market consists of sales of assisted reproductive technology (ART) by entities (organizations, sole traders, and partnerships) that are used for the treatment of infertility in either eggs or embryos.
  • The main types of assisted reproductive technology are in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo replacement (FER), and others.
  • Global Assisted Reproductive Technology Market, Segmentation By Diagnosis, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Inherent Biosciences Launches Path Fertility - Epigenetic Sperm Quality Test (SpermQT)

Retrieved on: 
Monday, October 18, 2021
Artificial insemination, LinkedIn, Gene, Doctor of Philosophy, Man, Congress, Pain, Translation, Semen analysis, Infertility, AI, Manuscript, Artificial intelligence, DNA, IUI, Male, Patient, CLIA, Biology, GLOBE, DNA methylation, Society, IVF, Semen, Inherence, SALT, COO, CAP, MD, In vitro fertilisation, Female, Hope, Medical device, Birth control

SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inherent Biosciences , a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the launch of Path Fertility's Epigenetic Sperm Quality Test, SpermQTTM at the American Society for Reproductive Medicine Scientific Congress & Expo.

Key Points: 
  • SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inherent Biosciences , a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the launch of Path Fertility's Epigenetic Sperm Quality Test, SpermQTTM at the American Society for Reproductive Medicine Scientific Congress & Expo.
  • SpermQT analyzes epigenetic patterns (DNA methylation) on genes associated with sperm production, sperm maturation, and embryo development.
  • "We now have a diagnostic that significantly improves the measurement of sperm quality," said Alex Pastuszak, MD, Ph.D., Inherent Biosciences clinical advisor.
  • About Inherent Biosciences - Inherent Biosciences, Inc. is a molecular diagnostics company at the intersection of epigenetics and AI.

INVO Bioscience to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Retrieved on: 
Thursday, August 5, 2021
Company, ART, Investor relations, Fertilisation, Private Securities Litigation Reform Act, Securities Act of 1933, Patient, Artificial insemination, Securities Exchange Act of 1934, Infertility, List of life sciences, Assisted reproductive technology, Multimedia, Fertility, In vitro fertilisation, IVC, Nasdaq, Egg

SARASOTA, Fla., Aug. 5, 2021 /PRNewswire/ --INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its second quarter 2021, ended June 30, 2021, after the market close on Monday, August 16, 2021.

Key Points: 
  • SARASOTA, Fla., Aug. 5, 2021 /PRNewswire/ --INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its second quarter 2021, ended June 30, 2021, after the market close on Monday, August 16, 2021.
  • The Company has scheduled a conference call that same day, Monday, August 16, 2021, at 4:30 pm ET, to review the results.
  • Replay:A teleconference replay of the call will be available through August 23, 2021 at 877-344-7529 or 412-317-0088, confirmation # 10158496.
  • A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days.

The Howard And Georgeanna Jones Foundation For Reproductive Medicine Announces The Creation Of A New Educational Program For REI Fellows And Practitioners: Jones Rounds

Retrieved on: 
Thursday, August 5, 2021
ART, Public policy, Research, Policy, Fellows, Howard, Reproductive medicine, Accreditation Council for Graduate Medical Education, Foundation, W. Alton Jones Foundation, Medicine, ARts, Georgetown University Complementary and Alternative Medicine Program, Religious response to assisted reproductive technology, Program, Board, Infertility, Fertility preservation, Grand Rounds, National, Multimedia, JD, Recreational Equipment, Inc., In vitro fertilisation, Party, Obstetrics and gynaecology, Kennedy Institute of Ethics, Communist crimes (Polish legal concept), Assisted Human Reproduction Canada, Education, Interior design

VIRGINIA BEACH, Va., Aug. 5, 2021 /PRNewswire/ -- The Howard and Georgeanna Jones Foundation for Reproductive Medicine ("Jones Foundation") is pleased to announce the creation of Jones Rounds -- an innovative, inter-disciplinary educational program honoring the remarkable vision and legacy of Dr. Howard W. Jones, Jr. Jones Rounds is designed to explore in depth the intersection of assisted reproductive technology (ART) medicine, law and ethics for Fellows and other practitioners interested in reproductive endocrinology and infertility (REI).

Key Points: 
  • VIRGINIA BEACH, Va., Aug. 5, 2021 /PRNewswire/ -- The Howard and Georgeanna Jones Foundation for Reproductive Medicine ("Jones Foundation") is pleased to announce the creation of Jones Rounds -- an innovative, inter-disciplinary educational program honoring the remarkable vision and legacy of Dr. Howard W. Jones, Jr. Jones Rounds is designed to explore in depth the intersection of assisted reproductive technology (ART) medicine, law and ethics for Fellows and other practitioners interested in reproductive endocrinology and infertility (REI).
  • Two Grand Rounds topics address the legal and ethical aspects of: 1) IVF and embryos; and 2) 3rd Party ART, which provide the springboard for a selection of 90-minute didactic modules.
  • Piloted modules to date include posthumous reproduction, fertility preservation, reproductive tissue disposition, and gestational surrogacy.
  • The Howard and Georgeanna Jones Foundation for Reproductive Medicine is a 501(c)(3) organization that solicits funds from the general public to support scientific and medical research and education in the field of reproductive medicine.

CCRM Fertility Announces New Satellite Office in Fargo

Retrieved on: 
Thursday, August 5, 2021
Essentia, National Committee, Chief executive officer, Research, Industry, American Association of Clinical Endocrinologists, Reproductive medicine, Science, University of North Dakota School of Medicine and Health Sciences, Genetic testing, University, Quality assurance, Obstetrics, Fertility, Partnership, Fertility clinic, Gynaecology, Patient, Essentia Health, Infertility, Essence, Western Colorado Center for the Arts, Reproduction, Department, Fertility preservation, Multimedia, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Knowledge, In vitro fertilisation, Hospital, National Committee for Quality Assurance, Accountable care organization, Physician, Medical device

FARGO, N.D., Aug. 5, 2021 /PRNewswire/ -- CCRM Fertility , a global pioneer in fertility treatment, research and science, today announced the expansion of its Minneapolis treatment network with the opening of a new satellite office within Essentia Health-Fargo, 3000 32nd Avenue South in Fargo, North Dakota.

Key Points: 
  • FARGO, N.D., Aug. 5, 2021 /PRNewswire/ -- CCRM Fertility , a global pioneer in fertility treatment, research and science, today announced the expansion of its Minneapolis treatment network with the opening of a new satellite office within Essentia Health-Fargo, 3000 32nd Avenue South in Fargo, North Dakota.
  • Beginning August 30, reproductive endocrinologist Dr. Stephanie Dahl will see patients out of the CCRM Minneapolis Fargo office, located at Essentia Health.
  • The new Fargo satellite office will offer individuals and couples a convenient location to experience a range offertility services, includingnew patient consultations, treatment planning, regroups, and monitoring (blood work and ultrasounds).
  • Founded by Dr. William Schoolcraft in 1987, CCRM (Colorado Center for Reproductive Medicine)Fertilityis the nation's leader in fertility care and research.

China Assisted Reproduction Market Insight Report, 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
General Health, Health, Family, Consumer, Articles, Fertility medicine, Medical specialties, Academic disciplines, Infertility, China, Reproduction, Assisted reproductive technology, Reproductive medicine

The "China Assisted Reproduction Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Assisted Reproduction Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • By the end of 2019, there were about 308 million women aged 21-49 in China, that is, about 38.5 million-46.2 million women of school age suffered from infertility.
  • To sum up, China's assisted reproductive industry has three characteristics: great market development potential, uneven distribution of assisted reproductive service resources, and strong dependence on imports of assisted reproductive medicines and instruments.
  • Great market development potential: 9.6 million infertile couples, with a market demand gap of 375.3 billion yuan to be met.

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

Retrieved on: 
Wednesday, August 4, 2021
Reproduction, Human reproduction, Obstetrics, Fertility medicine, Cryobiology, Fertility, In vitro fertilisation, Human pregnancy, Embryo transfer, Pregnancy rate, Meta-analysis, Randomized controlled trial

The first paper, entitled Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomized clinical trials (Griesinger et al), was published in the Journal of Human Reproduction.

Key Points: 
  • The first paper, entitled Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomized clinical trials (Griesinger et al), was published in the Journal of Human Reproduction.
  • The study reports the results from a meta-analysis of three randomized, placebo-controlled trials showing that nolasiban increased the likelihood of live birth following IVF.
  • The analyses also showed that the effect size for nolasiban was similar for ongoing pregnancy rate and live birth rate.
  • Population pharmacokinetic analyses indicated that higher exposures of nolasiban were associated with a higher probability of pregnancy.